Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease

被引:102
|
作者
Noguchi, M [1 ]
Hiwatashi, N [1 ]
Liu, Z [1 ]
Toyota, T [1 ]
机构
[1] Tohoku Univ, Sch Med, Dept Internal Med 3, Aoba Ku, Sendai, Miyagi 98077, Japan
关键词
Crohn's disease; inflammation; mucosal immunology; soluble TNF receptor; tumour necrosis factor; ulcerative colitis;
D O I
10.1136/gut.43.2.203
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background-Tumour necrosis factor (TNF) alpha and TNF-beta are soluble ligands binding to TNF receptors with similar activities; soluble TNF receptors neutralise TNF activity by acting as inhibitors. Little is known about the cytokine/soluble receptor role in inflammatory bowel disease (IBD). Aims-To test the hypothesis that an imbalance in secretion between TNF and TNF inhibitors plays a role in gut inflammation in patients with IBD. Methods-The secretion of TNF-alpha, TNF-beta, and soluble TNF receptors was compared in the culture supernatants of colonic biopsy specimens and isolated lamina propria mononuclear cells from patients with active colonic IBD. Results-Spontaneous secretion of TNF-alpha in involved IBD mucosa was higher than in normal control and self limited colitis mucosa. Secretion of TNF-beta was higher in patients with Crohn's disease than in those with ulcerative colitis. Soluble TNF receptor in IBD mucosa inhibited TNF activity. Type 2 soluble receptor release from IBD mucosa was increased in active inflammation; release from lamina propria cells was not increased. Mucosal TNF-alpha production correlated with severity of disease. Conclusions-Results showed enhanced secretion of TNF-alpha but failure to release enhanced amounts of soluble TNF receptor in lamina propria mononuclear cells of patients with IBD. An imbalance in secretion between TNF and TNF inhibitor may be implicated in the pathogenesis of IBD.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 50 条
  • [1] Tumour necrosis factor and inflammatory bowel disease
    Densem, CG
    BRITISH JOURNAL OF SURGERY, 1998, 85 (01) : 138 - 138
  • [2] Tumour necrosis factor and inflammatory bowel disease
    Armstrong, AM
    Gardiner, KR
    Kirk, SJ
    Halliday, MI
    Rowlands, BJ
    BRITISH JOURNAL OF SURGERY, 1997, 84 (08) : 1051 - 1058
  • [3] Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
    Peyrin-Biroulet, Laurent
    Sandborn, William J.
    Panaccione, Remo
    Domenech, Eugeni
    Pouillon, Lieven
    Siegmund, Britta
    Danese, Silvio
    Ghosh, Subrata
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [4] Tumour Necrosis Factor Superfamily Members in the Pathogenesis of Inflammatory Bowel Disease
    Slebioda, Tomasz J.
    Kmiec, Zbigniew
    MEDIATORS OF INFLAMMATION, 2014, 2014
  • [5] Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease
    Konstantinos Papamichael
    Severine Vermeire
    World Journal of Gastroenterology, 2015, (16) : 4773 - 4778
  • [6] Tumour necrosis factor α inhibitors:: screening for tuberculosis infection in inflammatory bowel disease
    Gupta, Arun
    Street, Alan C.
    Macrae, Finlay A.
    MEDICAL JOURNAL OF AUSTRALIA, 2008, 188 (03) : 168 - 170
  • [7] Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease
    Papamichael, Konstantinos
    Vermeire, Severine
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (16) : 4773 - 4778
  • [8] Tumour necrosis factor α promoter polymorphisms influence disease phenotype and severity in childhood inflammatory bowel disease
    Van Limbergen, J
    Russell, RK
    Nimmo, ER
    Drummond, HE
    Anderson, N
    Wilson, DC
    Gillett, PM
    McGrogan, P
    Hassan, K
    Weaver, LT
    Bisset, WM
    Mahdi, G
    Satsangi, J
    GUT, 2006, 55 : A10 - A10
  • [9] Anti-tumour necrosis factor α antibodies and circulating lymphocyte phenotypes in inflammatory bowel disease
    Defendenti, Caterina
    Tarkowski, Maciej
    Borille, Simona
    Cassinotti, Andrea
    Massari, Alessandro
    Birindelli, Sarah
    Riva, Agostino
    Ardizzone, Sandro
    Panteghini, Mauro
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 100
  • [10] Osteonecrosis of the jaw in patients with inflammatory bowel disease treated with tumour necrosis factor alpha inhibitors
    Brijs, K.
    Miclotte, I
    Vermeire, S.
    Darche, V
    Politis, C.
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2020, 49 (03) : 317 - 324